Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Total Current Liabilities: 2017-2024

Historic Total Current Liabilities for Dianthus Therapeutics (DNTH) over the last 6 years, with Dec 2024 value amounting to $18.5 million.

  • Dianthus Therapeutics' Total Current Liabilities rose 51.85% to $23.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 51.85%. This contributed to the annual value of $18.5 million for FY2024, which is 91.59% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Total Current Liabilities stood at $18.5 million for FY2024, which was up 91.59% from $9.6 million recorded in FY2023.
  • Dianthus Therapeutics' Total Current Liabilities' 5-year high stood at $18.5 million during FY2024, with a 5-year trough of $8.2 million in FY2022.
  • Over the past 3 years, Dianthus Therapeutics' median Total Current Liabilities value was $9.6 million (recorded in 2023), while the average stood at $12.1 million.
  • Data for Dianthus Therapeutics' Total Current Liabilities shows a peak YoY surged of 91.59% (in 2024) over the last 5 years.
  • Dianthus Therapeutics' Total Current Liabilities (Yearly) stood at $8.2 million in 2022, then climbed by 17.09% to $9.6 million in 2023, then surged by 91.59% to $18.5 million in 2024.